Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 1 · 25%Moderate 1 · 25%High 0 · 0%

RISPERIDONE vs placebo

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

RISPERIDONE may leads to lower leaving the study early ‐ short term (up to 12 weeks) ‐ any reason compared with PLACEBO (low certainty).

1 finding from 1 review

Risperidone versus placebo for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.69 [0.62, 0.78]
12 studies · 2261 participants
Low

RISPERIDONE DEPOT vs RISPERIDONE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.28 [0.92, 1.79]
2 studies · 690 participants
Moderate

CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

1 finding from 1 review

Risperidone versus placebo for schizophrenia 2016 · Cochrane Headline outcomes only
1.13 [0.53, 2.42]
3 studies · 167 participants
Very low

RISPERIDONE DEPOT vs placebo

Leaving the study early · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ all doses risperidone depot ‐… compared with PLACEBO (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.74 [0.63, 0.88]
1 study · 400 participants
Very low